Enzalutamide , ≥98% , 915087-33-1

CAS NO.：915087-33-1

Empirical Formula: C21H16F4N4O2S

Molecular Weight: 464.44

MDL number: MFCD14155804

EINECS: 805-022-1

PRODUCT Properties

• Melting point: 198 - 200°C
• Density: 1.49
• storage temp.: -20°C
• solubility: Soluble in DMSO (>25 mg/ml)
• form: solid
• pka: 13.88±0.46(Predicted)
• color: White to off-white
• Stability: Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Description and Uses

In August 2012, the US FDA approved enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously been treated with docetaxel. Synthesis of enzalutamide was achieved by a triply convergent route that employed a Strecker condensation, followed by isothiocyanate condensation and hydrolysis to form the thiohydantoin moiety. In LNCaP/AR cells with high expression of AR, enzalutamide demonstrated potent inhibition of 16b-[18F]-5α-dihydrotestosterone binding (IC₅₀=21 nM compared with bicalutamide IC₅₀=160 nM), and inhibited AR translocation to the nucleus more potently than bicalutamide.The primary metabolite is the result of CYP2C8-mediated N-demethylation; enzalutamide is primarily eliminated by hepatic metabolism.

MDV3100, known as Enzalutamide, is a second-generation androgen receptor (AR) signaling inhibitor. It is able to inhibit binding of androgens to the AR, AR nuclear translocation, and the association of the AR with DNA.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H227
• Precautionary statements: P501-P210-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313-P403+P235
• HS Code: 29339900